Paper Details

  1. Home
  2. Paper Details

Prasterone: A Review in Vulvovaginal Atrophy.

Author: HeoYoung-A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study explores the effectiveness and safety of intravaginal prasterone (Intrarosa®) for the treatment of vulvovaginal atrophy (VVA) in postmenopausal women. Intravaginal prasterone significantly improved signs and symptoms of VVA and was generally well tolerated, making it a promising therapeutic option for this condition.
Paper Details　
Original Abstract of the Article :
Vulvovaginal atrophy (VVA) is a progressive condition commonly seen in postmenopausal women. The cessation of ovarian estrogen secretion and a fall in serum levels of dehydroepiandrosterone (DHEA), the remaining source of estrogens and androgens, are thought to promote the development of VVA in this...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40266-019-00693-6

データ提供：米国国立医学図書館（NLM）

Prasterone: A Camel's Perspective on Vulvovaginal Atrophy

The field of [gynecology] is constantly searching for effective treatments for [vulvovaginal atrophy (VVA)]. This research examines the use of [prasterone], a synthetic form of [dehydroepiandrosterone (DHEA)], for treating [VVA] in [postmenopausal women]. The authors reviewed clinical trials and found that [prasterone] significantly improved the signs and symptoms of [VVA], offering a potential new treatment option for this condition. This research sheds light on the potential benefits of [prasterone] for managing [VVA] and improving [quality of life] for [postmenopausal women].

A New Oasis for Vulvovaginal Atrophy: The Promise of Prasterone

This research offers a glimmer of hope for women experiencing the discomfort of [vulvovaginal atrophy (VVA)]. Clinical trials have demonstrated that [prasterone] is effective in alleviating the symptoms of [VVA], improving [vaginal health] and [quality of life]. The study's findings highlight the potential for [prasterone] to become a valuable treatment option for [postmenopausal women] facing this condition.

Camel's Thoughts on Vulvovaginal Atrophy

Just as a camel adapts to the arid desert, women experience changes in their bodies during [menopause]. This research explores a potential solution for [vulvovaginal atrophy (VVA)], offering a way to manage the changes associated with [menopause] and improve [quality of life].

Dr. Camel's Conclusion

This research presents promising findings for the treatment of [vulvovaginal atrophy (VVA)] in [postmenopausal women]. The study highlights the potential benefits of [prasterone] in improving [vaginal health] and [quality of life]. It's a reminder that, just as a camel can find a refreshing oasis in the desert, women can find relief and improved well-being through innovative treatments for [vulvovaginal atrophy (VVA)].

Date :
  1. Date Completed 2019-11-25
  2. Date Revised 2020-03-09
Further Info :

Pubmed ID

31290076

DOI: Digital Object Identifier

10.1007/s40266-019-00693-6

Related Literature

Article Analysis
・Effects of prasterone vaginal
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.